Oruka files retroactively adjusted pre-merger audited financials as of Feb 6, 2024

Oruka Therapeutics, Inc.

Balance sheet shows $1K subscription receivable, zero cash; total stockholders' equity $1K.
Auditor's report includes going concern qualification due to no revenue and operating losses.
Adjustments reflect 1-for-12 reverse stock split and 6.8569 exchange ratio from August 2024 merger.
No new operational or financial information beyond the previously closed business combination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.